Pictet Asset Management
TVTX icon

Pictet Asset Management’s Travere Therapeutics TVTX Stock Holding History

Pictet Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Sell
529,757
-4,857
-0.9% -$145K 0.02% 569
2025
Q4 		$20.8M Sell
534,614
-149,770
-22% -$4.87M 0.02% 528
2025
Q3 		$16.5M Buy
684,384
+88,703
+15% +$1.67M 0.02% 564
2025
Q2 		$8.8M Sell
595,681
-69,889
-11% -$1.16M 0.01% 681
2025
Q1 		$13.1M Sell
665,570
-43,820
-6% -$889K 0.01% 594
2024
Q4 		$12.4M Sell
709,390
-53,518
-7% -$947K 0.01% 607
2024
Q3 		$10.7M Sell
762,908
-215,046
-22% -$2.24M 0.01% 633
2024
Q2 		$8.04M Sell
977,954
-1,260,914
-56% -$8.49M 0.01% 677
2024
Q1 		$17.2M Sell
2,238,868
-128,010
-5% -$1.08M 0.02% 522
2023
Q4 		$21.3M Buy
2,366,878
+226,338
+11% +$1.65M 0.02% 477
2023
Q3 		$19.1M Buy
+2,140,540
New +$30.2M 0.02% 468

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pictet Asset Management's TVTX Position: Q1 2026 in Review

Pictet Asset Management reduced its Travere Therapeutics (TVTX) stake by 0.91% in Q1 2026, selling an estimated $145K and leaving 529,757 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #569.

Pictet Asset Management first reported a position in TVTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $21.3M in Q4 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Pictet Asset Management held 529,757 shares of Travere Therapeutics worth $14.7M as of Q1 2026.
  • Pictet Asset Management sold 4,857 Travere Therapeutics shares in Q1 2026, an estimated $145K.
  • Travere Therapeutics made up 0.02% of Pictet Asset Management's portfolio in Q1 2026, its #569 holding.
  • Pictet Asset Management first reported a position in Travere Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Travere Therapeutics position peaked at $21.3M in Q4 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.